Companies: 10,795·Total market cap: $144.5T
10x Genomics, Inc.

10x Genomics, Inc.

TXGNASDAQHealthcare● Active
$29.18
$-1.86(-5.99%)
Market Cap$3.7B
P/E Ratio
52W High$32.31
52W Low$8.945
Overview

10x Genomics, Inc. (TXG) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

txg · stock forecast · 22 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 22 Wall Street analysts in the past 3 months

SellBuy

Hold

22 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
10
Hold
11
Sell
1
Strong Sell
0
Total: 22 · Buy rate: 45.5%

12-Month Price Target

High

$30.00

Consensus

$22.43

-23.1% upside

Low

$17.00

Median: $22 · Last Close: $29.18

The 10x Genomics, Inc. (TXG) analyst consensus is Hold, based on ratings from 22 Wall Street analysts over the past 3 months. The average 12-month TXG price target is $22.43, representing -23.1% upside from the current price of $29.18.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $22 (-23.1%)

Consensus Target

$22.43

-23.1% upside

High Target

$30

2.8%

Low Target

$17

-41.7%

Current Price

$29.18

as of today

Based on analyst price targets, the TXG stock price prediction for the next 12 months ranges from $17 to $30. The consensus TXG price forecast of $22.43 implies -23.1% upside from the current price of $29.18.

Short-Term Price Prediction

Bull

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$30.645.00%

1-day model range: $30.38–$30.89. Peak: $30.89 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$19-35.1%
2028$15-48.8%
2029$13-55.2%
2030$12-58.6%
2031-60.5%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

64%0%36%
9Buy
0Neutral
5Sell
RSI (14)71.0Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · TXG · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$31.32SELL
MA 10$29.26SELL
MA 20$25.70BUY
MA 50$23.79BUY
MA 100$21.94BUY
MA 200$18.41BUY
Current $TXG · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$30.41SELL
EMA 10$29.19SELL
EMA 20$27.08BUY
EMA 50$24.34BUY
EMA 100$22.16BUY
EMA 200$19.70BUY
Current $TXG · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
JP Morgan2026-05-12
Maintains
NeutralNeutral
Morgan Stanley2026-05-12
Maintains
Equal WeightEqual Weight
Canaccord Genuity2026-04-20
Maintains
BuyBuy
B of A Securities2026-04-20
Maintains
NeutralNeutral
Barclays2026-04-14
Maintains
OverweightOverweight
Citigroup2026-04-07
Maintains
NeutralNeutral
William Blair2026-03-31
Upgrade ↑
Market PerformOutperform
Stifel2026-03-02
Maintains
BuyBuy
UBS2026-02-20
Maintains
NeutralNeutral
TD Cowen2026-02-13
Maintains
HoldHold

Wall Street analysts have recently issued updated ratings on 10x Genomics, Inc. (TXG) stock. Of the recent 136 rating actions, 3 were upgrades and 13 were downgrades. 22 analysts currently cover TXG.

Analyst Recommendation Trends

Buy ratings202
Hold ratings22
Sell ratings00

TXG analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$613M

↓ 14.3% YoY

Revenue Next Year

$665M

↑ 8.4% YoY

EPS This Year

$-0.76

EPS Next Year

$-0.64

↓ 15.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast TXG EPS of $-0.76 for the current fiscal year, based on estimates from 7 analysts. The TXG revenue forecast is $613M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The TXG stock forecast is supported by two independent data sources: analyst consensus ratings from 22 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TXG price target is $22.43 (-23.1% upside), with an analyst consensus of Hold.

The TXG short-term stock prediction for tomorrow is $30.64 (+5.00%). The TXG stock price prediction for 2027 estimates an average of $19. The TXG stock prediction for 2030 projects a range of $11–$13.

10x Genomics, Inc. trades on NASDAQ under the ticker TXG. The TXG stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 45% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

TXG forecast · 8 questions

According to 22 Wall Street analysts, the average 12-month TXG price target is $22.43, with a high forecast of $30.00 and a low of $17.00. The median price target is shown in the chart above when available. This implies -23.1% potential upside from the current price of $29.18.

TXG price targetWhat is TXG price targetTXG analyst price targetTXG 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.